date:Mar 26, 2013
medicine and of molecular and medical pharmacology.
Previous studies performed by Fogelman's lab and other researchers around the world in animal models of disease have suggested that a large number of conditions with an inflammatory component not just atherosclerosis might benefit from treatment with an apoA-1 mimetic peptide, including Alzheimer's disease, ovarian and colon cancer, diabetes, asthma, and other disorders.
The immune system normally triggers an inflammatory response to an a